Minnesota’s Role in a Groundbreaking Medical Advance
Imagine being one of the first people in the country to try a treatment that could change the course of Alzheimer’s disease. For Kathy Ingebrand of Mahtomedi, MN, this isn’t just a possibility—it’s her reality.

Diagnosed at just 59, Kathy is one of the first Americans to receive Kisunla, a newly FDA-approved treatment. Now on her fourth monthly infusion, she remains hopeful the drug will slow the disease’s progression, giving her and her family more time to create lasting memories.

What to Know About Kisunla:

• Purpose: Slows Alzheimer’s progression by up to 35%, targeting harmful amyloid proteins in the brain.
• Cost: $695.65 per vial, with Kathy’s insurance covering the expense.
• Side Effects: Kathy has experienced only mild symptoms like nausea and fatigue.

“It’s not a cure, but it’s keeping me stable,” Kathy shared. “Maybe down the road, there will be another medication to add to this that will help cure it.”

A Family’s Emotional Journey
The Ingebrand family has found strength and hope in this treatment. Kathy’s husband, Pete, remembers the moment he shared the news: “I told her, ‘You’re going to be on the infusion.’ She left her grocery cart and cried all the way home.”

Their story is one of resilience and love, showing that even in the face of life’s challenges, breakthroughs can bring new hope.

Commitment to Senior Care
At American Baptist Homes of the Midwest, headquartered in Minnesota, we are inspired by the progress in Alzheimer’s treatments and the strength of individuals like Kathy who are pioneering this journey. Our goal is to provide compassionate care and innovative solutions to support seniors at every stage of life.